GSK plc (GSK) Form 6-K — Jul 28, 2026
GSK's licensor Hansoh Pharma announced that the ARTEMIS-011 Phase III trial of Ris-Rez in relapsed osteosarcoma met its primary endpoint of progression-free survival. The study demonstrated statistically significant and clinically meaningful improvements compared to chemotherapy, with consistent benefits observed in overall survival. GSK holds exclusive global rights to Ris-Rez outside Greater China and is advancing the drug in a global Phase Ib/II trial for sarcomas.
Key figures
- Osteosarcoma Incidence Per Million
- 3.4
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.